ישראל - עברית - Ministry of Health

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 20 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 40 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - rosuvastatin as calcium - טבליה - rosuvastatin as calcium 10 mg - rosuvastatin

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - rosuvastatin as calcium - טבליה - rosuvastatin as calcium 20 mg - rosuvastatin

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - rosuvastatin as calcium - טבליה - rosuvastatin as calcium 40 mg - rosuvastatin

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - rosuvastatin as calcium - טבליה - rosuvastatin as calcium 5 mg - rosuvastatin

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa